Insider Transactions in Q4 2022 at Biohaven Pharmaceutical Holding CO Ltd. (BHVN)
Insider Transaction List (Q4 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 03
2022
|
John W Childs |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
10,000
-100.0%
|
$1,480,000
$148.5 P/Share
|
|
Oct 03
2022
|
John W Childs |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,025,001
-100.0%
|
$447,700,148
$148.5 P/Share
|
|
Oct 03
2022
|
Vlad Coric Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
830,891
-47.14%
|
$122,971,868
$148.5 P/Share
|
|
Oct 03
2022
|
Vlad Coric Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
92,050
-9.97%
|
$13,623,400
$148.5 P/Share
|
|
Oct 03
2022
|
William A Jones Jr CCO-Migraine & Common Disease |
SELL
Sale (or disposition) back to the issuer
|
Direct |
14,226
-100.0%
|
$2,105,448
$148.5 P/Share
|
|
Oct 03
2022
|
Robert J Hugin |
SELL
Sale (or disposition) back to the issuer
|
Direct |
2,900
-100.0%
|
$429,200
$148.5 P/Share
|
|
Oct 03
2022
|
Matthew Buten Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
6,177
-100.0%
|
$914,196
$148.5 P/Share
|
|
Oct 03
2022
|
Kishan Mehta |
SELL
Sale (or disposition) back to the issuer
|
Direct |
10,640
-100.0%
|
$1,574,720
$148.5 P/Share
|
|
Oct 03
2022
|
John Tilton Chief Commercial Officer |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
1,614
-100.0%
|
$238,872
$148.5 P/Share
|
|
Oct 03
2022
|
John Tilton Chief Commercial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
5,068
-75.85%
|
$750,064
$148.5 P/Share
|
|
Oct 03
2022
|
James Engelhart Strategic Advisor |
SELL
Sale (or disposition) back to the issuer
|
Direct |
15,900
-100.0%
|
$2,353,200
$148.5 P/Share
|
|
Oct 03
2022
|
George C. Clark VP, Chief Accounting Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
4,292
-100.0%
|
$635,216
$148.5 P/Share
|
|
Oct 03
2022
|
Elyse Stock Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
5,374
-100.0%
|
$795,352
$148.5 P/Share
|
|
Oct 03
2022
|
Elyse Stock Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
11,090
-100.0%
|
$1,641,320
$148.5 P/Share
|
|
Oct 03
2022
|
Charles Conway Chief Scientific Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
22,362
-100.0%
|
$3,309,576
$148.5 P/Share
|
|
Oct 03
2022
|
Kimberly Gentile SVP, Clinical Operations |
SELL
Sale (or disposition) back to the issuer
|
Direct |
11,653
-100.0%
|
$1,724,644
$148.5 P/Share
|
|
Oct 03
2022
|
Gregory Bailey |
SELL
Sale (or disposition) back to the issuer
|
Direct |
2,583,658
-100.0%
|
$382,381,384
$148.5 P/Share
|